Alterations and Co-Occurrence of C-MYC, N-MYC, and L-MYC Expression are Related to Clinical Outcomes in Various Cancers
- Author:
Moonjung LEE
1
;
Jaekwon SEOK
;
Subbroto Kumar SAHA
;
Sungha CHO
;
Yeojin JEONG
;
Minchan GIL
;
Aram KIM
;
Ha Youn SHIN
;
Hojae BAE
;
Jeong Tae DO
;
Young Bong KIM
;
Ssang-Goo CHO
Author Information
- Publication Type:ORIGINAL ARTICLE
- From:International Journal of Stem Cells 2023;16(2):215-233
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background and Objectives:MYC, also known as an oncogenic reprogramming factor, is a multifunctional transcription factor that maintains induced pluripotent stem cells (iPSCs). Although MYC is frequently upregulated in various cancers and is correlated with a poor prognosis, MYC is downregulated and correlated with a good prognosis in lung adenocarcinoma. MYC and two other MYC family genes, MYCN and MYCL, have similar structures and could contribute to tumorigenic conversion both in vitro and in vivo.
Methods:and Results: We systematically investigated whether MYC family genes act as prognostic factors in various human cancers. We first evaluated alterations in the expression of MYC family genes in various cancers using the Oncomine and The Cancer Genome Atlas (TCGA) database and their mutation and copy number alterations using the TCGA database with cBioPortal. Then, we investigated the association between the expression of MYC family genes and the prognosis of cancer patients using various prognosis databases. Multivariate analysis also confirmed that co-expression of MYC/MYCL/MYCN was significantly associated with the prognosis of lung, gastric, liver, and breast cancers.
Conclusions:Taken together, our results demonstrate that the MYC family can function not only as an oncogene but also as a tumor suppressor gene in various cancers, which could be used to develop a novel approach to cancer treatment.
